Trial Profile
A Randomized, Multicenter, Phase II Trial of Cisplatin, Irinotecan and Bevacizumab (PCA) vs. Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Bevacizumab; Cisplatin; Irinotecan
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Oct 2022 Status changed from active, no longer recruiting to completed.
- 07 Jul 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 09 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.